State Street Corp Affimed N.V. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.32 - $0.62 $3,944 - $7,641	12,325 Added 2.38%	529,362 $328,000
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.65 $20,164 - $28,492	-43,835 Reduced 7.82%	517,037 $248,000
Q2 2023 Aug 14, 2023	SELL	$0.57 - $1.08 $1.12 Million - $2.12 Million	-1,962,795 Reduced 77.78%	560,872 $336,000
Q1 2023 May 15, 2023	BUY	$0.66 - $1.29 $95,290 - $186,250	144,380 Added 6.07%	2,523,667 $1.89 Million
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $25,944 - $57,785	23,586 Added 1.0%	2,379,287 $2.95 Million
Q3 2022 Nov 15, 2022	BUY	$1.96 - $3.32 $219,945 - $372,560	112,217 Added 5.0%	2,355,701 $4.85 Million
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $296,398 - $634,579	130,572 Added 6.18%	2,243,484 $6.21 Million
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $250,038 - $382,849	67,761 Added 3.31%	2,112,912 $9.23 Million
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $122,269 - $160,976	22,769 Added 1.13%	2,045,151 $11.3 Million
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $283,105 - $383,776	51,102 Added 2.59%	2,022,382 $12.5 Million
Q2 2021 Aug 16, 2021	SELL	$7.78 - $11.4 $236,823 - $347,016	-30,440 Reduced 1.52%	1,971,280 $16.8 Million
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $2.06 Million - $3.41 Million	401,936 Added 25.12%	2,001,720 $15.8 Million
Q4 2020 Feb 16, 2021	BUY	$3.16 - $7.03 $32,200 - $71,635	10,190 Added 0.64%	1,599,784 $9.31 Million
Q3 2020 Nov 10, 2020	BUY	$3.26 - $4.73 $312,630 - $453,602	95,899 Added 6.42%	1,589,594 $5.39 Million
Q2 2020 Aug 14, 2020	BUY	$1.58 - $4.63 $478,740 - $1.4 Million	303,000 Added 25.45%	1,493,695 $6.89 Million
Q1 2020 May 11, 2020	BUY	$1.44 - $3.02 $1.71 Million - $3.6 Million	1,190,695 New	1,190,695 $1.88 Million

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account